Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 5th edition, 486 pages

Free download


  Lung Cancer

  Free Subscription


Articles published in Oncogene

Retrieve available abstracts of 174 articles:
HTML format



Single Articles


    October 2020
  1. TUMBRINK HL, Heimsoeth A, Sos ML
    The next tier of EGFR resistance mutations in lung cancer.
    Oncogene. 2020 Oct 15. pii: 10.1038/s41388-020-01510.
    PubMed     Abstract available


  2. SHEN H, Wang GC, Li X, Ge X, et al
    S6K1 blockade overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
    Oncogene. 2020 Oct 9. pii: 10.1038/s41388-020-01497.
    PubMed     Abstract available


    September 2020
  3. WANG K, Ji W, Yu Y, Li Z, et al
    Correction: FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial-mesenchymal transition, and metastasis in FGFR1-amplified lung cancer.
    Oncogene. 2020 Sep 7. pii: 10.1038/s41388-020-01441.
    PubMed     Abstract available


    August 2020
  4. ZHANG X, Li F, Tang Y, Ren Q, et al
    miR-21a in exosomes from Lewis lung carcinoma cells accelerates tumor growth through targeting PDCD4 to enhance expansion of myeloid-derived suppressor cells.
    Oncogene. 2020 Aug 27. pii: 10.1038/s41388-020-01406.
    PubMed     Abstract available


  5. LI C, Zhao W, Pan X, Li X, et al
    LncRNA KTN1-AS1 promotes the progression of non-small cell lung cancer via sponging of miR-130a-5p and activation of PDPK1.
    Oncogene. 2020 Aug 20. pii: 10.1038/s41388-020-01427.
    PubMed     Abstract available


  6. ZHU Y, Li J, Bo H, He D, et al
    LINC00467 is up-regulated by TDG-mediated acetylation in non-small cell lung cancer and promotes tumor progression.
    Oncogene. 2020 Aug 14. pii: 10.1038/s41388-020-01421.
    PubMed     Abstract available


    July 2020
  7. ROH JI, Lee J, Sung YH, Oh J, et al
    Impaired AKT signaling and lung tumorigenesis by PIERCE1 ablation in KRAS-mutant non-small cell lung cancer.
    Oncogene. 2020 Jul 29. pii: 10.1038/s41388-020-01399.
    PubMed     Abstract available


    May 2020
  8. KWON OS, Lee H, Kong HJ, Kwon EJ, et al
    Connectivity map-based drug repositioning of bortezomib to reverse the metastatic effect of GALNT14 in lung cancer.
    Oncogene. 2020 May 9. pii: 10.1038/s41388-020-1316.
    PubMed     Abstract available


  9. HSIEN LAI S, Zervoudakis G, Chou J, Gurney ME, et al
    PDE4 subtypes in cancer.
    Oncogene. 2020;39:3791-3802.
    PubMed     Abstract available


    April 2020
  10. TIAN Q, Yuan P, Quan C, Li M, et al
    Phosphorylation of BCKDK of BCAA catabolism at Y246 by Src promotes metastasis of colorectal cancer.
    Oncogene. 2020 Apr 1. pii: 10.1038/s41388-020-1262.
    PubMed     Abstract available


  11. LI F, Li Z, Han Q, Cheng Y, et al
    Enhanced autocrine FGF19/FGFR4 signaling drives the progression of lung squamous cell carcinoma, which responds to mTOR inhibitor AZD2104.
    Oncogene. 2020;39:3507-3521.
    PubMed     Abstract available


  12. LI Y, Zhang H, Fan L, Mou J, et al
    MiR-629-5p promotes the invasion of lung adenocarcinoma via increasing both tumor cell invasion and endothelial cell permeability.
    Oncogene. 2020;39:3473-3488.
    PubMed     Abstract available


  13. KASIRI S, Chen B, Wilson AN, Reczek A, et al
    Stromal Hedgehog pathway activation by IHH suppresses lung adenocarcinoma growth and metastasis by limiting reactive oxygen species.
    Oncogene. 2020;39:3258-3275.
    PubMed     Abstract available


    March 2020
  14. WANG Y, Ma R, Liu B, Kong J, et al
    SNP rs17079281 decreases lung cancer risk through creating an YY1-binding site to suppress DCBLD1 expression.
    Oncogene. 2020 Mar 30. pii: 10.1038/s41388-020-1278.
    PubMed     Abstract available


  15. ARNAL-ESTAPE A, Cai WL, Albert AE, Zhao M, et al
    Tumor progression and chromatin landscape of lung cancer are regulated by the lineage factor GATA6.
    Oncogene. 2020 Mar 10. pii: 10.1038/s41388-020-1246.
    PubMed     Abstract available


  16. CHAN YC, Chang YC, Chuang HH, Yang YC, et al
    Overexpression of PSAT1 promotes metastasis of lung adenocarcinoma by suppressing the IRF1-IFNgamma axis.
    Oncogene. 2020;39:2509-2522.
    PubMed     Abstract available


    February 2020
  17. SALIAKOURA M, Reynoso-Moreno I, Pozzato C, Rossi Sebastiano M, et al
    The ACSL3-LPIAT1 signaling drives prostaglandin synthesis in non-small cell lung cancer.
    Oncogene. 2020 Feb 7. pii: 10.1038/s41388-020-1196.
    PubMed     Abstract available


  18. TONG X, Wang S, Lei Z, Li C, et al
    MYOCD and SMAD3/SMAD4 form a positive feedback loop and drive TGF-beta-induced epithelial-mesenchymal transition in non-small cell lung cancer.
    Oncogene. 2020 Feb 6. pii: 10.1038/s41388-020-1189.
    PubMed     Abstract available


  19. REBOLLIDO-RIOS R, Venton G, Sanchez-Redondo S, Iglesias I Felip C, et al
    Dual disruption of aldehyde dehydrogenases 1 and 3 promotes functional changes in the glutathione redox system and enhances chemosensitivity in nonsmall cell lung cancer.
    Oncogene. 2020 Feb 3. pii: 10.1038/s41388-020-1184.
    PubMed     Abstract available


  20. HUANG J, Lan X, Wang T, Lu H, et al
    Targeting the IL-1beta/EHD1/TUBB3 axis overcomes resistance to EGFR-TKI in NSCLC.
    Oncogene. 2020;39:1739-1755.
    PubMed     Abstract available


  21. ZHANG Q, Fan H, Liu H, Jin J, et al
    WNT5B exerts oncogenic effects and is negatively regulated by miR-5587-3p in lung adenocarcinoma progression.
    Oncogene. 2020;39:1484-1497.
    PubMed     Abstract available


    January 2020
  22. QI M, Dai D, Liu J, Li Z, et al
    AIM2 promotes the development of non-small cell lung cancer by modulating mitochondrial dynamics.
    Oncogene. 2020 Jan 31. pii: 10.1038/s41388-020-1176.
    PubMed     Abstract available


  23. YU S, Sha H, Qin X, Chen Y, et al
    EGFR E746-A750 deletion in lung cancer represses antitumor immunity through the exosome-mediated inhibition of dendritic cells.
    Oncogene. 2020 Jan 30. pii: 10.1038/s41388-020-1182.
    PubMed     Abstract available


  24. ZHANG J, Lin X, Wu L, Huang JJ, et al
    Aurora B induces epithelial-mesenchymal transition by stabilizing Snail1 to promote basal-like breast cancer metastasis.
    Oncogene. 2020 Jan 29. pii: 10.1038/s41388-020-1165.
    PubMed     Abstract available


  25. CHAUHAN SS, Toth RK, Jensen CC, Casillas AL, et al
    PIM kinases alter mitochondrial dynamics and chemosensitivity in lung cancer.
    Oncogene. 2020 Jan 28. pii: 10.1038/s41388-020-1168.
    PubMed     Abstract available


  26. WU X, Zhang X, Yu L, Zhang C, et al
    Zinc finger protein 367 promotes metastasis by inhibiting the Hippo pathway in breast cancer.
    Oncogene. 2020 Jan 27. pii: 10.1038/s41388-020-1166.
    PubMed     Abstract available


  27. MARTIN-PADRON J, Boyero L, Rodriguez MI, Andrades A, et al
    Correction: Plakophilin 1 enhances MYC translation, promoting squamous cell lung cancer.
    Oncogene. 2020 Jan 13. pii: 10.1038/s41388-019-1147.
    PubMed     Abstract available


  28. LIU Y, Mao C, Wang M, Liu N, et al
    Cancer progression is mediated by proline catabolism in non-small cell lung cancer.
    Oncogene. 2020 Jan 7. pii: 10.1038/s41388-019-1151.
    PubMed     Abstract available


  29. DIAS MM, Adamoski D, Dos Reis LM, Ascencao CFR, et al
    GLS2 is protumorigenic in breast cancers.
    Oncogene. 2020;39:690-702.
    PubMed     Abstract available


  30. SMEESTER BA, Slipek NJ, Pomeroy EJ, Bomberger HE, et al
    SEMA4C is a novel target to limit osteosarcoma growth, progression, and metastasis.
    Oncogene. 2020;39:1049-1062.
    PubMed     Abstract available


    December 2019
  31. JIN Y, Bao H, Le X, Fan X, et al
    Correction: Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation.
    Oncogene. 2019 Dec 12. pii: 10.1038/s41388-019-1143.
    PubMed     Abstract available


  32. MARTIN-PADRON J, Boyero L, Rodriguez MI, Andrades A, et al
    Plakophilin 1 enhances MYC translation, promoting squamous cell lung cancer.
    Oncogene. 2019 Dec 10. pii: 10.1038/s41388-019-1129.
    PubMed     Abstract available


  33. SEMBA S, Trapasso F, Fabbri M, McCorkell KA, et al
    Correction: Fhit modulation of the Akt-survivin pathway in lung cancer cells: Fhit-tyrosine 114 (Y114) is essential.
    Oncogene. 2019 Dec 9. pii: 10.1038/s41388-019-1130.
    PubMed     Abstract available


    November 2019
  34. JIN Y, Bao H, Le X, Fan X, et al
    Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation.
    Oncogene. 2019 Nov 21. pii: 10.1038/s41388-019-1104.
    PubMed     Abstract available


  35. MORENO LEON L, Gautier M, Allan R, Ilie M, et al
    The nuclear hypoxia-regulated NLUCAT1 long non-coding RNA contributes to an aggressive phenotype in lung adenocarcinoma through regulation of oxidative stress.
    Oncogene. 2019;38:7146-7165.
    PubMed     Abstract available


    October 2019
  36. ZHANGYUAN G, Wang F, Zhang H, Jiang R, et al
    VersicanV1 promotes proliferation and metastasis of hepatocellular carcinoma through the activation of EGFR-PI3K-AKT pathway.
    Oncogene. 2019 Oct 11. pii: 10.1038/s41388-019-1052.
    PubMed     Abstract available


  37. SHIN SB, Jang HR, Xu R, Won JY, et al
    Correction: Active PLK1-driven metastasis is amplified by TGF-beta signaling that forms a positive feedback loop in non-small cell lung cancer.
    Oncogene. 2019 Oct 8. pii: 10.1038/s41388-019-1049.
    PubMed     Abstract available


  38. SALAMA MF, Liu M, Clarke CJ, Espaillat MP, et al
    Correction: PKCalpha is required for Akt-mTORC1 activation in non-small cell lung carcinoma (NSCLC) with EGFR mutation.
    Oncogene. 2019 Oct 1. pii: 10.1038/s41388-019-1019.
    PubMed     Abstract available


    September 2019
  39. SINGH K, Pruski MA, Polireddy K, Jones NC, et al
    Mst1/2 kinases restrain transformation in a novel transgenic model of Ras driven non-small cell lung cancer.
    Oncogene. 2019 Sep 30. pii: 10.1038/s41388-019-1031.
    PubMed     Abstract available


  40. HSU YL, Huang MS, Hung JY, Chang WA, et al
    Bone-marrow-derived cell-released extracellular vesicle miR-92a regulates hepatic pre-metastatic niche in lung cancer.
    Oncogene. 2019 Sep 26. pii: 10.1038/s41388-019-1024.
    PubMed     Abstract available


  41. SHIN SB, Jang HR, Xu R, Won JY, et al
    Active PLK1-driven metastasis is amplified by TGF-beta signaling that forms a positive feedback loop in non-small cell lung cancer.
    Oncogene. 2019 Sep 23. pii: 10.1038/s41388-019-1023.
    PubMed     Abstract available


  42. ESTEVES P, Dard L, Brillac A, Hubert C, et al
    Nuclear control of lung cancer cells migration, invasion and bioenergetics by eukaryotic translation initiation factor 3F.
    Oncogene. 2019 Sep 16. pii: 10.1038/s41388-019-1009.
    PubMed     Abstract available


  43. CAI L, Lin S, Girard L, Zhou Y, et al
    Correction: LCE: an open web portal to explore gene expression and clinical associations in lung cancer.
    Oncogene. 2019 Sep 9. pii: 10.1038/s41388-019-1000.
    PubMed     Abstract available


  44. LIN SC, Lin CH, Shih NC, Liu HL, et al
    Cellular prion protein transcriptionally regulated by NFIL3 enhances lung cancer cell lamellipodium formation and migration through JNK signaling.
    Oncogene. 2019 Sep 2. pii: 10.1038/s41388-019-0994.
    PubMed     Abstract available


  45. ZENG F, Wang Q, Wang S, Liang S, et al
    Linc00173 promotes chemoresistance and progression of small cell lung cancer by sponging miR-218 to regulate Etk expression.
    Oncogene. 2019 Sep 2. pii: 10.1038/s41388-019-0984.
    PubMed     Abstract available


    August 2019
  46. SALAMA MF, Liu M, Clarke CJ, Espaillat MP, et al
    PKCalpha is required for Akt-mTORC1 activation in non-small cell lung carcinoma (NSCLC) with EGFR mutation.
    Oncogene. 2019 Aug 16. pii: 10.1038/s41388-019-0950.
    PubMed     Abstract available


  47. YANG R, Liu N, Chen L, Jiang Y, et al
    GIAT4RA functions as a tumor suppressor in non-small cell lung cancer by counteracting Uchl3-mediated deubiquitination of LSH.
    Oncogene. 2019 Aug 15. pii: 10.1038/s41388-019-0909.
    PubMed     Abstract available


  48. GOBBI G, Donati B, Do Valle IF, Reggiani F, et al
    The Hippo pathway modulates resistance to BET proteins inhibitors in lung cancer cells.
    Oncogene. 2019 Aug 12. pii: 10.1038/s41388-019-0924.
    PubMed     Abstract available


  49. LI MY, Peng WH, Wu CH, Chang YM, et al
    PTPN3 suppresses lung cancer cell invasiveness by counteracting Src-mediated DAAM1 activation and actin polymerization.
    Oncogene. 2019 Aug 12. pii: 10.1038/s41388-019-0948.
    PubMed     Abstract available


  50. JALLOW F, O'Leary KA, Rugowski DE, Guerrero JF, et al
    Dynamic interactions between the extracellular matrix and estrogen activity in progression of ER+ breast cancer.
    Oncogene. 2019 Aug 12. pii: 10.1038/s41388-019-0941.
    PubMed     Abstract available


  51. LIAO SY, Kuo IY, Chen YT, Liao PC, et al
    AKT-mediated phosphorylation enhances protein stability and transcription activity of ZNF322A to promote lung cancer progression.
    Oncogene. 2019 Aug 9. pii: 10.1038/s41388-019-0928.
    PubMed     Abstract available


  52. SUN QY, Ding LW, Johnson K, Zhou S, et al
    SOX7 regulates MAPK/ERK-BIM mediated apoptosis in cancer cells.
    Oncogene. 2019;38:6196-6210.
    PubMed     Abstract available


  53. KIM SJ, Garcia-Recio S, Creighton CJ, Perou CM, et al
    Alterations in Wnt- and/or STAT3 signaling pathways and the immune microenvironment during metastatic progression.
    Oncogene. 2019;38:5942-5958.
    PubMed     Abstract available


    July 2019
  54. RAOOF S, Mulford IJ, Frisco-Cabanos H, Nangia V, et al
    Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer.
    Oncogene. 2019 Jul 19. pii: 10.1038/s41388-019-0887.
    PubMed     Abstract available


  55. YAO S, Huang HY, Han X, Ye Y, et al
    Keratin 14-high subpopulation mediates lung cancer metastasis potentially through Gkn1 upregulation.
    Oncogene. 2019 Jul 18. pii: 10.1038/s41388-019-0889.
    PubMed     Abstract available


  56. NOEPARAST A, Giron P, Noor A, Bahadur Shahi R, et al
    CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition.
    Oncogene. 2019 Jul 8. pii: 10.1038/s41388-019-0866.
    PubMed     Abstract available


    June 2019
  57. SAIGI M, Alburquerque-Bejar JJ, Sanchez-Cespedes M
    Determinants of immunological evasion and immunocheckpoint inhibition response in non-small cell lung cancer: the genetic front.
    Oncogene. 2019 Jun 28. pii: 10.1038/s41388-019-0855.
    PubMed     Abstract available


  58. ZHOU L, Jiang Y, Liu X, Li L, et al
    Promotion of tumor-associated macrophages infiltration by elevated neddylation pathway via NF-kappaB-CCL2 signaling in lung cancer.
    Oncogene. 2019 Jun 26. pii: 10.1038/s41388-019-0840.
    PubMed     Abstract available


  59. YAMAGUCHI T, Hayashi M, Ida L, Yamamoto M, et al
    ROR1-CAVIN3 interaction required for caveolae-dependent endocytosis and pro-survival signaling in lung adenocarcinoma.
    Oncogene. 2019;38:5142-5157.
    PubMed     Abstract available


    May 2019
  60. LU CH, Yeh DW, Lai CY, Liu YL, et al
    Correction: USP17 mediates macrophage-promoted inflammation and stemness in lung cancer cells by regulating TRAF2/TRAF3 complex formation.
    Oncogene. 2019 May 30. pii: 10.1038/s41388-019-0831.
    PubMed     Abstract available


  61. SEPULT C, Bellefroid M, Rocks N, Donati K, et al
    ADAM10 mediates malignant pleural mesothelioma invasiveness.
    Oncogene. 2019;38:3521-3534.
    PubMed     Abstract available


  62. HUANG JJ, Corona AL, Dunn BP, Cai EM, et al
    Increased type III TGF-beta receptor shedding decreases tumorigenesis through induction of epithelial-to-mesenchymal transition.
    Oncogene. 2019;38:3402-3414.
    PubMed     Abstract available


  63. BLIJLEVENS M, van der Meulen-Muileman IH, de Menezes RX, Smit EF, et al
    High-throughput RNAi screening reveals cancer-selective lethal targets in the RNA spliceosome.
    Oncogene. 2019;38:4142-4153.
    PubMed     Abstract available


  64. TEW BY, Legendre C, Gooden GC, Johnson KN, et al
    Isolation and characterization of patient-derived CNS metastasis-associated stromal cell lines.
    Oncogene. 2019;38:4002-4014.
    PubMed     Abstract available


  65. ROSENFELD YB, Krumbein M, Yeffet A, Schiffmann N, et al
    VICKZ1 enhances tumor progression and metastasis in lung adenocarcinomas in mice.
    Oncogene. 2019;38:4169-4181.
    PubMed     Abstract available


  66. TANG B, Wu J, Zhu MX, Sun X, et al
    VPAC1 couples with TRPV4 channel to promote calcium-dependent gastric cancer progression via a novel autocrine mechanism.
    Oncogene. 2019;38:3946-3961.
    PubMed     Abstract available


    April 2019
  67. DUAN L, Perez RE, Chastain PD 2nd, Mathew MT, et al
    JMJD2 promotes acquired cisplatin resistance in non-small cell lung carcinoma cells.
    Oncogene. 2019 Apr 9. pii: 10.1038/s41388-019-0814.
    PubMed     Abstract available


  68. GE X, Li GY, Jiang L, Jia L, et al
    Long noncoding RNA CAR10 promotes lung adenocarcinoma metastasis via miR-203/30/SNAI axis.
    Oncogene. 2019;38:3061-3076.
    PubMed     Abstract available


  69. ABDELWAHAB EMM, Pal S, Kvell K, Sarosi V, et al
    Mitochondrial dysfunction is a key determinant of the rare disease lymphangioleiomyomatosis and provides a novel therapeutic target.
    Oncogene. 2019;38:3093-3101.
    PubMed     Abstract available


  70. NISHIMURA T, Nakata A, Chen X, Nishi K, et al
    Cancer stem-like properties and gefitinib resistance are dependent on purine synthetic metabolism mediated by the mitochondrial enzyme MTHFD2.
    Oncogene. 2019;38:2464-2481.
    PubMed     Abstract available


    March 2019
  71. CASADO-MEDRANO V, Barrio-Real L, Wang A, Cooke M, et al
    Distinctive requirement of PKCepsilon in the control of Rho GTPases in epithelial and mesenchymally transformed lung cancer cells.
    Oncogene. 2019 Mar 28. pii: 10.1038/s41388-019-0796.
    PubMed     Abstract available


  72. FEDOROVA O, Petukhov A, Daks A, Shuvalov O, et al
    Orphan receptor NR4A3 is a novel target of p53 that contributes to apoptosis.
    Oncogene. 2019;38:2108-2122.
    PubMed     Abstract available


  73. MATSUSHITA A, Sato T, Mukai S, Fujishita T, et al
    TAZ activation by Hippo pathway dysregulation induces cytokine gene expression and promotes mesothelial cell transformation.
    Oncogene. 2019;38:1966-1978.
    PubMed     Abstract available


  74. ZHANG C, Wang H, Liu X, Hu Y, et al
    Oncogenic microRNA-411 promotes lung carcinogenesis by directly targeting suppressor genes SPRY4 and TXNIP.
    Oncogene. 2019;38:1892-1904.
    PubMed     Abstract available


  75. WANG C, Gu Y, Zhang E, Zhang K, et al
    A cancer-testis non-coding RNA LIN28B-AS1 activates driver gene LIN28B by interacting with IGF2BP1 in lung adenocarcinoma.
    Oncogene. 2019;38:1611-1624.
    PubMed     Abstract available


  76. HSU FF, Chou YT, Chiang MT, Li FA, et al
    Signal peptide peptidase promotes tumor progression via facilitating FKBP8 degradation.
    Oncogene. 2019;38:1688-1701.
    PubMed     Abstract available


    February 2019
  77. ZHANG H, Wang Y, Dou J, Guo Y, et al
    Acetylation of AGO2 promotes cancer progression by increasing oncogenic miR-19b biogenesis.
    Oncogene. 2019;38:1410-1431.
    PubMed     Abstract available


  78. DE BOER HR, Pool M, Joosten E, Everts M, et al
    Quantitative proteomics analysis identifies MUC1 as an effect sensor of EGFR inhibition.
    Oncogene. 2019;38:1477-1488.
    PubMed     Abstract available


  79. YONESAKA K, Takegawa N, Watanabe S, Haratani K, et al
    An HER3-targeting antibody-drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC.
    Oncogene. 2019;38:1398-1409.
    PubMed     Abstract available


  80. LIN SC, Chung CH, Chung CH, Kuo MH, et al
    OCT4B mediates hypoxia-induced cancer dissemination.
    Oncogene. 2019;38:1093-1105.
    PubMed     Abstract available


  81. BOUDRIA A, Abou Faycal C, Jia T, Gout S, et al
    VEGF165b, a splice variant of VEGF-A, promotes lung tumor progression and escape from anti-angiogenic therapies through a beta1 integrin/VEGFR autocrine loop.
    Oncogene. 2019;38:1050-1066.
    PubMed     Abstract available


  82. FANG L, Wu S, Zhu X, Cai J, et al
    MYEOV functions as an amplified competing endogenous RNA in promoting metastasis by activating TGF-beta pathway in NSCLC.
    Oncogene. 2019;38:896-912.
    PubMed     Abstract available


    January 2019
  83. CAO J, Zhu Z, Wang H, Nichols TC, et al
    Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer.
    Oncogene. 2019 Jan 30. pii: 10.1038/s41388-019-0708.
    PubMed     Abstract available


  84. ZHU J, Huang G, Hua X, Li Y, et al
    CD44s is a crucial ATG7 downstream regulator for stem-like property, invasion, and lung metastasis of human bladder cancer (BC) cells.
    Oncogene. 2019 Jan 11. pii: 10.1038/s41388-018-0664.
    PubMed     Abstract available


  85. LIU L, Yang Y, Liu S, Tao T, et al
    EGF-induced nuclear localization of SHCBP1 activates beta-catenin signaling and promotes cancer progression.
    Oncogene. 2019;38:747-764.
    PubMed     Abstract available


  86. HAMAIDI I, Coquard C, Danilin S, Dormoy V, et al
    The Lim1 oncogene as a new therapeutic target for metastatic human renal cell carcinoma.
    Oncogene. 2019;38:60-72.
    PubMed     Abstract available


  87. PATEL Y, Soni M, Awgulewitsch A, Kern MJ, et al
    Overexpression of miR-489 derails mammary hierarchy structure and inhibits HER2/neu-induced tumorigenesis.
    Oncogene. 2019;38:445-453.
    PubMed     Abstract available


  88. WENG CH, Chen LY, Lin YC, Shih JY, et al
    Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI.
    Oncogene. 2019;38:455-468.
    PubMed     Abstract available


    December 2018
  89. WIESWEG M, Kasper S, Worm K, Herold T, et al
    Impact of RAS mutation subtype on clinical outcome-a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer.
    Oncogene. 2018 Dec 19. pii: 10.1038/s41388-018-0634.
    PubMed     Abstract available


  90. SHIRAI YT, Mizutani A, Nishijima S, Horie M, et al
    CNOT3 targets negative cell cycle regulators in non-small cell lung cancer development.
    Oncogene. 2018 Dec 10. pii: 10.1038/s41388-018-0603.
    PubMed     Abstract available


  91. GIANNI M, Terao M, Kurosaki M, Paroni G, et al
    S100A3 a partner protein regulating the stability/activity of RARalpha and PML-RARalpha in cellular models of breast/lung cancer and acute myeloid leukemia.
    Oncogene. 2018 Dec 7. pii: 10.1038/s41388-018-0599.
    PubMed     Abstract available


  92. CAI L, Lin S, Girard L, Zhou Y, et al
    LCE: an open web portal to explore gene expression and clinical associations in lung cancer.
    Oncogene. 2018 Dec 7. pii: 10.1038/s41388-018-0588.
    PubMed     Abstract available


  93. MA A, Tang M, Zhang L, Wang B, et al
    USP1 inhibition destabilizes KPNA2 and suppresses breast cancer metastasis.
    Oncogene. 2018 Dec 7. pii: 10.1038/s41388-018-0590.
    PubMed     Abstract available


  94. TESSARI A, Parbhoo K, Pawlikowski M, Fassan M, et al
    RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients.
    Oncogene. 2018;37:6463-6476.
    PubMed     Abstract available


  95. OHNO Y, Shingyoku S, Miyake S, Tanaka A, et al
    Differential regulation of the sphere formation and maintenance of cancer-initiating cells of malignant mesothelioma via CD44 and ALK4 signaling pathways.
    Oncogene. 2018;37:6357-6367.
    PubMed     Abstract available


    November 2018
  96. FAN Z, Yang J, Zhang D, Zhang X, et al
    The risk variant rs884225 within EGFR impairs miR-103a-3p's anti-tumourigenic function in non-small cell lung cancer.
    Oncogene. 2018 Nov 23. pii: 10.1038/s41388-018-0576.
    PubMed     Abstract available


  97. BEST SA, Harapas CR, Kersbergen A, Rathi V, et al
    FGFR3-TACC3 is an oncogenic fusion protein in respiratory epithelium.
    Oncogene. 2018;37:6096-6104.
    PubMed     Abstract available


  98. OOKI A, Dinalankara W, Marchionni L, Tsay JJ, et al
    Epigenetically regulated PAX6 drives cancer cells toward a stem-like state via GLI-SOX2 signaling axis in lung adenocarcinoma.
    Oncogene. 2018;37:5967-5981.
    PubMed     Abstract available


    October 2018
  99. LEONG TL, Gayevskiy V, Steinfort DP, De Massy MR, et al
    Deep multi-region whole-genome sequencing reveals heterogeneity and gene-by-environment interactions in treatment-naive, metastatic lung cancer.
    Oncogene. 2018 Oct 22. pii: 10.1038/s41388-018-0536.
    PubMed     Abstract available


  100. SHIMIZU M, Tanaka N
    IL-8-induced O-GlcNAc modification via GLUT3 and GFAT regulates cancer stem cell-like properties in colon and lung cancer cells.
    Oncogene. 2018 Oct 10. pii: 10.1038/s41388-018-0533.
    PubMed     Abstract available


  101. KIM Y, Shiba-Ishii A, Nakagawa T, Iemura SI, et al
    Stratifin regulates stabilization of receptor tyrosine kinases via interaction with ubiquitin-specific protease 8 in lung adenocarcinoma.
    Oncogene. 2018;37:5387-5402.
    PubMed     Abstract available


  102. DI MODUGNO F, Spada S, Palermo B, Visca P, et al
    hMENA isoforms impact NSCLC patient outcome through fibronectin/beta1 integrin axis.
    Oncogene. 2018;37:5605-5617.
    PubMed     Abstract available


  103. LEE GW, Park JB, Park SY, Seo J, et al
    The E3 ligase C-CBL inhibits cancer cell migration by neddylating the proto-oncogene c-Src.
    Oncogene. 2018;37:5552-5568.
    PubMed     Abstract available


    September 2018
  104. BALAMURUGAN K, Mendoza-Villanueva D, Sharan S, Summers GH, et al
    C/EBPdelta links IL-6 and HIF-1 signaling to promote breast cancer stem cell-associated phenotypes.
    Oncogene. 2018 Sep 27. pii: 10.1038/s41388-018-0516.
    PubMed     Abstract available


  105. YU W, Ding J, He M, Chen Y, et al
    Estrogen receptor beta promotes the vasculogenic mimicry (VM) and cell invasion via altering the lncRNA-MALAT1/miR-145-5p/NEDD9 signals in lung cancer.
    Oncogene. 2018 Sep 24. pii: 10.1038/s41388-018-0463.
    PubMed     Abstract available


  106. LIN YP, Wu JI, Tseng CW, Chen HJ, et al
    Gjb4 serves as a novel biomarker for lung cancer and promotes metastasis and chemoresistance via Src activation.
    Oncogene. 2018 Sep 3. pii: 10.1038/s41388-018-0471.
    PubMed     Abstract available


    August 2018
  107. LIANG SQ, Buhrer ED, Berezowska S, Marti TM, et al
    mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer.
    Oncogene. 2018 Aug 31. pii: 10.1038/s41388-018-0479.
    PubMed     Abstract available


  108. YOCHUM ZA, Cades J, Wang H, Chatterjee S, et al
    Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer.
    Oncogene. 2018 Aug 31. pii: 10.1038/s41388-018-0482.
    PubMed     Abstract available


  109. LEE E, Ouzounova M, Piranlioglu R, Ma MT, et al
    The pleiotropic effects of TNFalpha in breast cancer subtypes is regulated by TNFAIP3/A20.
    Oncogene. 2018 Aug 30. pii: 10.1038/s41388-018-0472.
    PubMed     Abstract available


  110. HAN J, Wang F, Lan Y, Wang J, et al
    KIFC1 regulated by miR-532-3p promotes epithelial-to-mesenchymal transition and metastasis of hepatocellular carcinoma via gankyrin/AKT signaling.
    Oncogene. 2018 Aug 16. pii: 10.1038/s41388-018-0440.
    PubMed     Abstract available


  111. KIM IK, McCutcheon JN, Rao G, Liu SV, et al
    Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer.
    Oncogene. 2018 Aug 9. pii: 10.1038/s41388-018-0429.
    PubMed     Abstract available


  112. WEEDEN CE, Ah-Cann C, Holik AZ, Pasquet J, et al
    Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition.
    Oncogene. 2018;37:4475-4488.
    PubMed     Abstract available


  113. YUE J, Lv D, Wang C, Li L, et al
    Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin beta3.
    Oncogene. 2018;37:4300-4312.
    PubMed     Abstract available


    July 2018
  114. LU CH, Yeh DW, Lai CY, Liu YL, et al
    USP17 mediates macrophage-promoted inflammation and stemness in lung cancer cells by regulating TRAF2/TRAF3 complex formation.
    Oncogene. 2018 Jul 23. pii: 10.1038/s41388-018-0411.
    PubMed     Abstract available


  115. GLUCK AA, Orlando E, Leiser D, Poliakova M, et al
    Identification of a MET-eIF4G1 translational regulation axis that controls HIF-1alpha levels under hypoxia.
    Oncogene. 2018;37:4181-4196.
    PubMed     Abstract available


  116. CROSSLAND DL, Denning WL, Ang S, Olivares S, et al
    Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models.
    Oncogene. 2018;37:3686-3697.
    PubMed     Abstract available


  117. TANG Q, Lu J, Zou C, Shao Y, et al
    CDH4 is a novel determinant of osteosarcoma tumorigenesis and metastasis.
    Oncogene. 2018;37:3617-3630.
    PubMed     Abstract available


    June 2018
  118. WANG K, Ji W, Yu Y, Li Z, et al
    FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial-mesenchymal transition, and metastasis in FGFR1-amplified lung cancer.
    Oncogene. 2018 Jun 1. pii: 10.1038/s41388-018-0311.
    PubMed     Abstract available


  119. LAI SC, Phelps CA, Short AM, Dutta SM, et al
    Thyroid transcription factor 1 enhances cellular statin sensitivity via perturbing cholesterol metabolism.
    Oncogene. 2018;37:3290-3300.
    PubMed     Abstract available


  120. DANKNER M, Rose AAN, Rajkumar S, Siegel PM, et al
    Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.
    Oncogene. 2018;37:3183-3199.
    PubMed     Abstract available


    May 2018
  121. JI X, Qian J, Rahman SMJ, Siska PJ, et al
    xCT (SLC7A11)-mediated metabolic reprogramming promotes non-small cell lung cancer progression.
    Oncogene. 2018 May 23. pii: 10.1038/s41388-018-0307.
    PubMed     Abstract available


  122. ZHAO C, Li Y, Qiu W, He F, et al
    C5a induces A549 cell proliferation of non-small cell lung cancer via GDF15 gene activation mediated by GCN5-dependent KLF5 acetylation.
    Oncogene. 2018 May 18. pii: 10.1038/s41388-018-0298.
    PubMed     Abstract available


  123. WANG PS, Chou CH, Lin CH, Yao YC, et al
    A novel long non-coding RNA linc-ZNF469-3 promotes lung metastasis through miR-574-5p-ZEB1 axis in triple negative breast cancer.
    Oncogene. 2018 May 14. pii: 10.1038/s41388-018-0293.
    PubMed     Abstract available


  124. CHEN A, Sceneay J, Godde N, Kinwel T, et al
    Intermittent hypoxia induces a metastatic phenotype in breast cancer.
    Oncogene. 2018 May 1. pii: 10.1038/s41388-018-0259.
    PubMed     Abstract available


  125. ITOH H, Kadomatsu T, Tanoue H, Yugami M, et al
    TET2-dependent IL-6 induction mediated by the tumor microenvironment promotes tumor metastasis in osteosarcoma.
    Oncogene. 2018;37:2903-2920.
    PubMed     Abstract available


  126. REHRAUER H, Wu L, Blum W, Pecze L, et al
    How asbestos drives the tissue towards tumors: YAP activation, macrophage and mesothelial precursor recruitment, RNA editing, and somatic mutations.
    Oncogene. 2018;37:2645-2659.
    PubMed     Abstract available


    April 2018
  127. WANG S, Jia M, He Z, Liu XS, et al
    APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer.
    Oncogene. 2018 Apr 26. pii: 10.1038/s41388-018-0245.
    PubMed     Abstract available


  128. TOMOSHIGE K, Guo M, Tsuchiya T, Fukazawa T, et al
    An EGFR ligand promotes EGFR-mutant but not KRAS-mutant lung cancer in vivo.
    Oncogene. 2018 Apr 17. pii: 10.1038/s41388-018-0240.
    PubMed     Abstract available


  129. NEWMAN JH, Augeri DJ, NeMoyer R, Malhotra J, et al
    Novel bone morphogenetic protein receptor inhibitor JL5 suppresses tumor cell survival signaling and induces regression of human lung cancer.
    Oncogene. 2018 Apr 6. pii: 10.1038/s41388-018-0156.
    PubMed     Abstract available


  130. PENTIMALLI F, Forte IM, Esposito L, Indovina P, et al
    RBL2/p130 is a direct AKT target and is required to induce apoptosis upon AKT inhibition in lung cancer and mesothelioma cell lines.
    Oncogene. 2018 Apr 2. pii: 10.1038/s41388-018-0214.
    PubMed     Abstract available


    March 2018
  131. MONTERISI S, Riso PL, Russo K, Bertalot G, et al
    HOXB7 overexpression in lung cancer is a hallmark of acquired stem-like phenotype.
    Oncogene. 2018 Mar 26. pii: 10.1038/s41388-018-0229.
    PubMed     Abstract available


  132. TANG J, Chen H, Wong CC, Liu D, et al
    DEAD-box helicase 27 promotes colorectal cancer growth and metastasis and predicts poor survival in CRC patients.
    Oncogene. 2018 Mar 14. pii: 10.1038/s41388-018-0196.
    PubMed     Abstract available


  133. MEDER L, Konig K, Dietlein F, Macheleidt I, et al
    LIN28B enhanced tumorigenesis in an autochthonous KRAS(G12V)-driven lung carcinoma mouse model.
    Oncogene. 2018 Mar 5. pii: 10.1038/s41388-018-0158.
    PubMed     Abstract available


    February 2018
  134. LAI Q, Wang H, Li A, Xu Y, et al
    Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells.
    Oncogene. 2018 Feb 9. pii: 10.1038/s41388-018-0125.
    PubMed     Abstract available


    January 2018
  135. ZHENG X, Chi J, Zhi J, Zhang H, et al
    Aurora-A-mediated phosphorylation of LKB1 compromises LKB1/AMPK signaling axis to facilitate NSCLC growth and migration.
    Oncogene. 2018;37:502-511.
    PubMed     Abstract available


  136. WELCKER D, Jain M, Khurshid S, Jokic M, et al
    AATF suppresses apoptosis, promotes proliferation and is critical for Kras-driven lung cancer.
    Oncogene. 2018 Jan 11. pii: 10.1038/s41388-017-0054.
    PubMed     Abstract available


  137. CORKERY DP, Clarke LE, Gebremeskel S, Salsman J, et al
    Loss of PRP4K drives anoikis resistance in part by dysregulation of epidermal growth factor receptor endosomal trafficking.
    Oncogene. 2018;37:174-184.
    PubMed     Abstract available


  138. CHIANG WF, Cheng TM, Chang CC, Pan SH, et al
    Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) promotes EGF receptor signaling of oral squamous cell carcinoma metastasis via the complex N-glycosylation.
    Oncogene. 2018;37:116-127.
    PubMed     Abstract available


  139. ORTH M, Unger K, Schoetz U, Belka C, et al
    Taxane-mediated radiosensitization derives from chromosomal missegregation on tripolar mitotic spindles orchestrated by AURKA and TPX2.
    Oncogene. 2018;37:52-62.
    PubMed     Abstract available


    November 2017
  140. SZYMICZEK A, Carbone M, Pastorino S, Napolitano A, et al
    Inhibition of the spindle assembly checkpoint kinase Mps-1 as a novel therapeutic strategy in malignant mesothelioma.
    Oncogene. 2017;36:6501-6507.
    PubMed     Abstract available


  141. ZHONG Y, Yang J, Xu WW, Wang Y, et al
    KCTD12 promotes tumorigenesis by facilitating CDC25B/CDK1/Aurora A-dependent G2/M transition.
    Oncogene. 2017;36:6177-6189.
    PubMed     Abstract available


  142. TORRENTE L, Sanchez C, Moreno R, Chowdhry S, et al
    Crosstalk between NRF2 and HIPK2 shapes cytoprotective responses.
    Oncogene. 2017;36:6204-6212.
    PubMed     Abstract available


  143. TRINIDAD AG, Whalley N, Rowlinson R, Delpuech O, et al
    Pyruvate dehydrogenase kinase 4 exhibits a novel role in the activation of mutant KRAS, regulating cell growth in lung and colorectal tumour cells.
    Oncogene. 2017;36:6164-6176.
    PubMed     Abstract available


    October 2017
  144. REN T, Zhang H, Wang J, Zhu J, et al
    MCU-dependent mitochondrial Ca2+ inhibits NAD+/SIRT3/SOD2 pathway to promote ROS production and metastasis of HCC cells.
    Oncogene. 2017;36:5897-5909.
    PubMed     Abstract available


  145. IVANOV AA, Gonzalez-Pecchi V, Khuri LF, Niu Q, et al
    OncoPPi-informed discovery of mitogen-activated protein kinase kinase 3 as a novel binding partner of c-Myc.
    Oncogene. 2017;36:5852-5860.
    PubMed     Abstract available


  146. SPOLVERINI A, Fuchs G, Bublik DR, Oren M, et al
    let-7b and let-7c microRNAs promote histone H2B ubiquitylation and inhibit cell migration by targeting multiple components of the H2B deubiquitylation machinery.
    Oncogene. 2017;36:5819-5828.
    PubMed     Abstract available


  147. CHHABRA Y, Wong HY, Nikolajsen LF, Steinocher H, et al
    A growth hormone receptor SNP promotes lung cancer by impairment of SOCS2-mediated degradation.
    Oncogene. 2017 Oct 2. doi: 10.1038/onc.2017.
    PubMed     Abstract available


    September 2017
  148. KATO T, Sato T, Yokoi K, Sekido Y, et al
    E-cadherin expression is correlated with focal adhesion kinase inhibitor resistance in Merlin-negative malignant mesothelioma cells.
    Oncogene. 2017;36:5522-5531.
    PubMed     Abstract available


  149. ZHANG Y, Hu Y, Wang JL, Yao H, et al
    Proteomic identification of ERP29 as a key chemoresistant factor activated by the aggregating p53 mutant Arg282Trp.
    Oncogene. 2017;36:5473-5483.
    PubMed     Abstract available


  150. ROWSON-HODEL AR, Wald JH, Hatakeyama J, O'Neal WK, et al
    Membrane Mucin Muc4 promotes blood cell association with tumor cells and mediates efficient metastasis in a mouse model of breast cancer.
    Oncogene. 2017 Sep 11. doi: 10.1038/onc.2017.
    PubMed     Abstract available


  151. KIM M, Jang K, Miller P, Picon-Ruiz M, et al
    VEGFA links self-renewal and metastasis by inducing Sox2 to repress miR-452, driving Slug.
    Oncogene. 2017;36:5199-5211.
    PubMed     Abstract available


  152. CHEN G, Zhang B, Xu H, Sun Y, et al
    Suppression of Sirt1 sensitizes lung cancer cells to WEE1 inhibitor MK-1775-induced DNA damage and apoptosis.
    Oncogene. 2017 Sep 4. doi: 10.1038/onc.2017.
    PubMed     Abstract available


  153. YAN F, Shen N, Pang J, Zhao N, et al
    A regulatory circuit composed of DNA methyltransferases and receptor tyrosine kinases controls lung cancer cell aggressiveness.
    Oncogene. 2017 Sep 4. doi: 10.1038/onc.2017.
    PubMed     Abstract available


    August 2017
  154. YURUGI H, Marini F, Weber C, David K, et al
    Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours.
    Oncogene. 2017;36:4778-4789.
    PubMed     Abstract available


    July 2017
  155. VELMURUGAN KR, Varghese RT, Fonville NC, Garner HR, et al
    High-depth, high-accuracy microsatellite genotyping enables precision lung cancer risk classification.
    Oncogene. 2017 Jul 31. doi: 10.1038/onc.2017.
    PubMed     Abstract available


  156. GARNETT S, Dutchak KL, McDonough RV, Dankort D, et al
    p53 loss does not permit escape from BrafV600E-induced senescence in a mouse model of lung cancer.
    Oncogene. 2017 Jul 24. doi: 10.1038/onc.2017.
    PubMed     Abstract available


  157. UMEDA Y, Hasegawa Y, Otsuka M, Ariki S, et al
    Surfactant protein D inhibits activation of non-small cell lung cancer-associated mutant EGFR and affects clinical outcomes of patients.
    Oncogene. 2017 Jul 24. doi: 10.1038/onc.2017.
    PubMed     Abstract available


  158. WU DW, Lee MC, Hsu NY, Wu TC, et al
    FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF-kappaB/Slug-mediated PUMA reduction.
    Oncogene. 2017 Jul 17. doi: 10.1038/onc.2017.
    PubMed     Abstract available


  159. WANG J, Jia Y, Zhao S, Zhang X, et al
    BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer.
    Oncogene. 2017 Jul 17. doi: 10.1038/onc.2017.
    PubMed     Abstract available


    June 2017
  160. NOTO A, De Vitis C, Pisanu ME, Roscilli G, et al
    Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ.
    Oncogene. 2017 Jun 19. doi: 10.1038/onc.2017.
    PubMed     Abstract available


  161. JEN J, Lin LL, Lo FY, Chen HT, et al
    Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer.
    Oncogene. 2017 Jun 19. doi: 10.1038/onc.2017.
    PubMed     Abstract available


  162. FENG J, Yang H, Zhang Y, Wei H, et al
    Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells.
    Oncogene. 2017 Jun 12. doi: 10.1038/onc.2017.
    PubMed     Abstract available


  163. SZCZEPNY A, Rogers S, Jayasekara WSN, Park K, et al
    The role of canonical and non-canonical Hedgehog signaling in tumor progression in a mouse model of small cell lung cancer.
    Oncogene. 2017 Jun 5. doi: 10.1038/onc.2017.
    PubMed     Abstract available


  164. LIAO SY, Chiang CW, Hsu CH, Chen YT, et al
    CK1delta/GSK3beta/FBXW7alpha axis promotes degradation of the ZNF322A oncoprotein to suppress lung cancer progression.
    Oncogene. 2017 Jun 5. doi: 10.1038/onc.2017.
    PubMed     Abstract available


  165. LI H, Xiao N, Wang Y, Wang R, et al
    Smurf1 regulates lung cancer cell growth and migration through interaction with and ubiquitination of PIPKIgamma.
    Oncogene. 2017 Jun 5. doi: 10.1038/onc.2017.
    PubMed     Abstract available


    May 2017
  166. WANG Q, Ma J, Lu Y, Zhang S, et al
    CDK20 interacts with KEAP1 to activate NRF2 and promotes radiochemoresistance in lung cancer cells.
    Oncogene. 2017 May 22. doi: 10.1038/onc.2017.
    PubMed     Abstract available


  167. CHOI EJ, Jung BJ, Lee SH, Yoo HS, et al
    A clinical drug library screen identifies clobetasol propionate as an NRF2 inhibitor with potential therapeutic efficacy in KEAP1 mutant lung cancer.
    Oncogene. 2017 May 15. doi: 10.1038/onc.2017.
    PubMed     Abstract available


    April 2017
  168. HSU YL, Hung JY, Chang WA, Lin YS, et al
    Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1.
    Oncogene. 2017 Apr 24. doi: 10.1038/onc.2017.
    PubMed     Abstract available


  169. AMBROGIO C, Barbacid M, Santamaria D
    In vivo oncogenic conflict triggered by co-existing KRAS and EGFR activating mutations in lung adenocarcinoma.
    Oncogene. 2017;36:2309-2318.
    PubMed     Abstract available


  170. LU W, Cheng F, Yan W, Li X, et al
    Selective targeting p53WT lung cancer cells harboring homozygous p53 Arg72 by an inhibitor of CypA.
    Oncogene. 2017 Apr 10. doi: 10.1038/onc.2017.
    PubMed     Abstract available


  171. OHM AM, Tan AC, Heasley LE, Reyland ME, et al
    Co-dependency of PKCdelta and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer.
    Oncogene. 2017 Apr 3. doi: 10.1038/onc.2017.
    PubMed     Abstract available


  172. JEN J, Lin LL, Lo FY, Chen HT, et al
    Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer.
    Oncogene. 2017 Apr 3. doi: 10.1038/onc.2017.
    PubMed    


  173. NOTO A, De Vitis C, Pisanu ME, Roscilli G, et al
    Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ.
    Oncogene. 2017 Apr 3. doi: 10.1038/onc.2017.
    PubMed     Abstract available


  174. SHAKYA R, Tarulli GA, Sheng L, Lokman NA, et al
    Mutant p53 upregulates alpha-1 antitrypsin expression and promotes invasion in lung cancer.
    Oncogene. 2017 Apr 3. doi: 10.1038/onc.2017.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: